HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beanlands, R. S.B. Articles by Schwaiger, M. Search for Related Content PubMed PubMed Citation Articles by Beanlands, R. S.B. Articles by Schwaiger, M.

The Kinetics of Copper-62-PTSM in the Normal Human Heart

Division of Nuclear Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For reprints contact: Dr. Markus Schwaiger, Director of Cardiovascular Nuclear Medicine, Division of Nuclear Medicine, UH B1G505, University of Michigan Medical Center, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0028.

ABSTRACT

Copper-62-labeled pyruvaldehyde bis(N-4-methylthiosemicarbazone) copper (II) (PTSM) is a generator-produced myocardial perfusion tracer. Animal studies have shown high myocardial tissue extraction and prolonged retention. The aim of this study was to define myocardial kinetics of ⁶²Cu-PTSM and to determine its suitability for evaluating myocardial perfusion at rest and during pharmacological vasodilation in human subjects. In six healthy volunteers, ⁶²Cu-PTSM was administered at baseline and during a 6-min adenosine infusion (140 µg/kg/min). Dynamic PET imaging with high temporal resolution was performed over 20 min. Good image quality was observed at rest and following adenosine. Myocardial kinetics demonstrated prolonged tissue retention with a clearance half-life of 105 ± 49 min at rest and 101 ± 65 min following adenosine (p = ns). Copper-62-PTSM tissue retention was quantified and showed only a 1.97-fold increase from rest to adenosine studies. This suggests attenuation of tracer retention at high flow rates. Copper-62-PTSM represents a promising new radiopharmaceutical for the evaluation of myocardial perfusion in the human heart.

This article has been cited by other articles:

				P. A. Kaufmann and P. G. Camici Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications J. Nucl. Med., January 1, 2005; 46(1): 75 - 88. [Full Text] [PDF]